Get the Stockscreener App
344.55
1.17%
-4.07
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $344.55, with a volume of 2.19M.
It is down -1.17% in the last 24 hours and down -1.11% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$348.62
Open:
$346
24h Volume:
2.19M
Relative Volume:
0.80
Market Cap:
$185.74B
Revenue:
$36.74B
Net Income/Loss:
$7.71B
P/E Ratio:
24.21
EPS:
14.2333
Net Cash Flow:
$8.10B
1W Performance:
-3.03%
1M Performance:
-1.11%
6M Performance:
+18.09%
1Y Performance:
+23.12%
1-Day Range:
$342.52
$347.66
1-Week Range:
$340.06
$356.90
52-Week Range:
$261.43
$391.29
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
344.55 | 185.74B | 36.74B | 7.71B | 8.10B | 14.23 |
LLY
Lilly Eli Co
|
883.96 | 789.69B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
227.50 | 547.64B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
198.71 | 351.47B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
189.75 | 294.27B | 58.80B | 10.24B | 8.98B | 3.2788 |
NVS
Novartis Ag Adr
|
145.47 | 277.58B | 54.72B | 14.02B | 15.32B | 7.1855 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Hold |
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen Inc. stock (US0311621009): Is its obesity drug pipeline strong enough to unlock new upside? - AD HOC NEWS
Vanguard Group Inc. Raises Stock Position in Amgen Inc. $AMGN - MarketBeat
A Look At Amgen (AMGN) Valuation As New AI Focused Leadership Team Takes Shape - simplywall.st
Amgen Inc. (NASDAQ:AMGN) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Amgen’s AI-Focused Leadership Reshuffle Could Be A Game Changer For Amgen (AMGN) - Yahoo Finance
Amgen Tracks Long-Term Romosozumab Safety in Children: What Investors Should Know - TipRanks
Amgen Stock (AMGN) Opinions on Q1 Earnings Preview - Quiver Quantitative
Amgen Inc. $AMGN Shares Sold by Mattern Capital Management LLC - MarketBeat
Amgen Inc. (AMGN) Announces Executive Leadership Transition - GuruFocus
5 Best Stem Cell Therapy Stocks to Buy - Insider Monkey
Wall Street Zen Downgrades Amgen (NASDAQ:AMGN) to Hold - MarketBeat
Amgen (AMGN) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
Robert Bradway: Biotech Veteran, Strategic Dealmaker, and Amgen Chairman and CEO - BBN Times
Q1 2026 results announcement pushes Amgen stock down 1.17% - Traders Union
Amgen posts Q1 results April 30; anyone can hear the webcast live - Stock Titan
AMGEN ANNOUNCES WEBCAST OF 2026 FIRST QUARTER FINANCIAL RESULTS - Yahoo Finance
Amgen Inc (FRA:AMG0) Stock Price & 30 Year Financial Data - GuruFocus
Merck, Amgen Share Losses Contribute To Dow's 168-Point Drop - Moomoo
Kerusso Capital Management LLC Purchases 3,196 Shares of Amgen Inc. $AMGN - MarketBeat
Quent Long Short Global Small Cap Fund LP Makes New $2.20 Million Investment in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Position Lessened by OLD National Bancorp IN - MarketBeat
Directional Asset Management Makes New $2.41 Million Investment in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN is China Universal Asset Management Co. Ltd.'s 9th Largest Position - MarketBeat
Amgen Inc. $AMGN Shares Sold by Arizona State Retirement System - MarketBeat
Large-scale manufacturing meets sustainability at Amgen campus in New Albany - Yahoo Finance
Chronic Obstructive Pulmonary Disease Clinical Trial Landscape Expands: Over 65 Companies Advancing Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
Amgen Marks Key Milestone With Completion of Early MTAP-Null Cancer Combo Study - TipRanks
David Reese retirement prompts organizational changes at Amgen - The Pharma Letter
Torray Investment Partners LLC Sells 7,883 Shares of Amgen Inc. $AMGN - MarketBeat
Earnings Preview: Amgen (AMGN) Q1 Earnings Expected to Decline - Yahoo Finance UK
Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Lowers Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by M&T Bank Corp - MarketBeat
Guggenheim Adjusts Amgen Inc. (AMGN) PT to $351, Cites Updated Model Ahead of Earnings - Insider Monkey
Amgen (AMGN) to Release Earnings on Thursday - MarketBeat
Boston Trust Walden Corp Has $23.54 Million Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen (NASDAQ:AMGN) Stock Acquired Rep. Maria Elvira Salazar - MarketBeat
Reese retiring after two decades at Amgen - biocentury.com
The Bull Case For Amgen (AMGN) Could Change Following Strong Q4 Beat And Upbeat 2026 Guidance - simplywall.st
Amgen (NASDAQ: AMGN) CTO David Reese to retire as company realigns AI and R&D - Stock Titan
Maria Elvira Salazar makes significant purchases in Amgen, Boeing, and Cisco By Investing.com - Investing.com South Africa
AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER - marketscreener.com
Amgen Announces Executive Changes, Effective June 1, 2026 - marketscreener.com
Maria Elvira Salazar makes significant purchases in Amgen, Boeing, and Cisco - Investing.com Canada
AMGN Amgen tops Q4 2025 earnings expectations, posts near 10 percent revenue growth, shares dip 1 percent.Acquisition - Cổng thông tin điện tử tỉnh Lào Cai
AMGQ Bond Risk Analysis - TradingView
Congressional Trading Report: Rep. Maria Elvira Salazar Bought Over $221K In Amgen Stock - Benzinga
Amgen Inc. $AMGN Shares Bought by KLP Kapitalforvaltning AS - MarketBeat
Is Amgen Stock Poised For A Rally? - Trefis
AMGN Stock Price, Quote & Chart | AMGEN INC (NASDAQ:AMGN) - ChartMill
Amgen Inc. (AMGN)Pre-Earnings Analysis Ahead of Fiscal Q1 2026 Results ReleasePerformance Review - Cổng thông tin điện tử tỉnh Lào Cai
Amgen Faces ERISA Suit Over Health Plan Tobacco Surcharge - Law360
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amgen Inc Stock (AMGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Santos Esteban | EVP, Operations |
Feb 26 '26 |
Option Exercise |
169.19 |
54,792 |
9,270,143 |
107,119 |
| Santos Esteban | EVP, Operations |
Feb 26 '26 |
Sale |
379.12 |
54,792 |
20,772,595 |
76,618 |
6.88%
2.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):